Hot Investor Mandate: Canada-Based VC Firm Seeking Companies in Digital Health and AI-Based Medical Devices in North America, Europe and GCC Region 

21 Apr

The firm is Canada’s leading healthcare VC Firm. Based in Toronto, the firm typically makes equity investments into digital health and AI enabled medical device companies at seed / series A-B stages and follow on rounds. The typical investment size ranges from $1.5 million to $ 7 million. The firm seeks to invest in approx. 2-5 digital health/AI enabled medical device companies per year and focuses on companies based in North America, Europe and the GCC region. 

The firm is currently looking for new investment opportunities in the Digital Health and AI enabled Medical Device spaces. The firm is opportunistic in terms of indications. The firm prefers to invest in non-invasive device companies with clinical validation and some in-human data with a clear path to clinical adoption & reimbursement. For Digital Health, the firm prefers to invest in companies developing data platforms aimed at improving outcomes or processes, with first market pilots complete and approx. $250k ARR. 

The firm seeks to invest in private companies. The firm considers pre-revenue companies, depending on sector and in companies who have has a strong commercial and technical management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

Hot Investor Mandate: USA Venture Firm Focused on Early-Stage Companies in AgeTech, Including Remote Monitoring, Caregiver Assistance, Digital Therapeutics, etc. 

21 Apr

The firm is an agetech-focused seed-stage VC firm, founded in 2016 and based in New York. The firm is focused on all aspects of agetech, whether helping older adults live at home longer, assisting caregivers or facilities in elder care. Within healthcare, the firm invests in companies such as digital health, digital therapeutics, and remote monitoring, among others. The firm currently invests in companies in North America, Europe and Israel, and will soon invest in Asia and the South Pacific as well. The firm generally invests $50-150K in companies that have demonstrated early signs of market traction, and may invest up to $300K over the lifetime of the investment. 

The firm will consider investments in any technology relating to agetech that does not require clinical trials. This can include companies developing technologies relating to remote monitoring, those assisting caregivers, digital therapeutics, among others. 

The firm generally co-invests. They can be as involved as the company requires, taking a more active role if they can be of assistance to the company in any way. 

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com. 

Last Chance to Save $300

14 Apr

By Antoinette Lowre, Manager of Business Development, LSN

When was the last time you attended a partnering conference? Fundraising is a numbers game and deals can take up to 9-18 months, so getting out (virtually or in-person) to meet with investors frequently can give you a competitive edge. Whether you’ve already added RESI to your partnering toolkit or not, Digital RESI, June 7-9 can offer value with the opportunities to meet virtually with 400 investors and strategic partners and even pitch live to a panel of investor-judges. Register before this Friday, April 15 to save $300 with the super early bird rate!

The super early bird is our best deal for a 3-day standard partnering registration. Startups are often strapped financially while prioritizing milestones and growth, which is why it’s important that RESI features deals to make partnering accessible to all. Additionally, Life Science Nation (LSN) hosts FREE branding and messaging fundraising bootcamps and Innovator’s Pitch Challenge info sessions to help answer any questions you may have about pitching at RESI.

Fundraising 101: Avoiding Pitfalls and Improving the Odds
  • Karen Deyo, Director, Investor Research, Israel Business Development, Life Science Nation
  • Candice He, Vice President, Business Development, Global Investment Strategist, Life Science Nation
This bootcamp is designed to help scientist-entrepreneurs navigate the world of fundraising. It starts out by debunking some commonly held misconceptions about early-stage startups and fundraising, followed by tips on how to improve your chances and increasing investor visibility.
Preparing to Pitch at RESI
  • Candice He, Vice President, Business Development, Global Investment Strategist, Life Science Nation
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. This bootcamp will walk through the process of preparing your pitch materials and what to expect in a live pitch session, including frequently asked questions from investor judges.
Strategies for Successful Partnering
  • Alexander Vassallo, Manager, Business Development, Life Science Nation
  • Joey Wong, Analyst, Investor Research, Hong Kong BD Life Science Nation
This bootcamp is a fan favorite with tried-and-true tips to make your partnering experience exceptional, letting your technology, product, and team take center-stage. Whether booking 1-on-1 meetings or pitching to a panel, these strategies will help you prioritize the details that make a difference in telling your story to potential investors and strategic partners.

If you’re looking to take your partnering to the next level, consider adding the premier package to increase your access to investor profiles ($500). Premier partnering grants you access to investor mandates in the LSN Investor Database, which includes direct emails to support your target list and facilitate year-round connection.

Know Your Competitive Landscape

14 Apr

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Do you know the players in your field that are developing similar technologies, or different technologies for the same application? Do you understand how your technology compares to those potential competitors? These are issues investors will want to see you have a grasp on, so having a clear vision of your Competitive Landscape will add a lot of value when you are pitching for investment.

Life Science Nation (LSN) offers valuable resources to early-stage companies as they seek funding and develop their strategies to grow and progress. To track your competitive landscape, LSN has a powerful business development database that tracks more than 60,000 companies across all the verticals of the life sciences and all stages of development. In just a few clicks, you can see your own competitive landscape.

Once you’ve seen the competitive landscape, it’s important to understand how to communicate your unique value. We can also help you understand and effectively communicate this, extracted in part from your better picture of the Competitive Landscape, through LSN’s Branding & Messaging consulting services. Experts will work with you to develop optimal marketing collateral for you to use in your communication with investors and partners, increasing your odds of success. Hear from Reglagene CEO Richard Austin on how he learned to tell his company story and how it impacted his early-stage fundraising.

Finally, you can put your enhanced market comprehension, communication skills and story to the test in the Innovator’s Pitch Challenge (IPC) at Digital RESI, June 7-9. The IPC is a fantastic showcase for founders who participate in a live Q&A from investors and strategic partners from different sectors in life science and healthcare. Investors frequently ask pitching founders about their unique value and market competition. A keen and well-communicated understanding of the competitive landscape shows investors that you don’t just function within an industry – you know it.

This knowledge can help you position yourself, not just accurately among competitors, but as someone who really knows their industry. To learn more about your competitive landscape or about any products or services mentioned, reach out to connect with LSN’s dedicated business development team.

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Alexander Vassallo
Manager of Business Development
Book a Meeting
Email Me

Preparing to Pitch with the End in Mind

14 Apr

By Rory McCann, Marketing Manager & Conference Producer, LSN

Bold Therapeutics is a clinical-stage pharma startup developing and commercializing novel therapeutics to combat drug resistance in cancer and infectious disease. At Digital RESI March, Bold Therapeutics founder Russell McAllister met success at the Innovator’s Pitch Challenge (IPC) and is sharing his perspectives from preparation to pitch to follow-up conversations. If you’re actively fundraising or considering pitching at RESI, check out our conversation and learn how Russell leveraged, not only his company, but his own unique experience to stand out at RESI.

IPC applications are still live until Friday, April 29. Get your application in by Friday, April 15 to save on super early bird rates!

Hot Investor Mandate: VC Firm with Firm US and China Presence With Multiple Billions AUM Invests Up to $20M Across All Life Science Industries

14 Apr

A venture capital firm founded in China with over $4 billion in total managed assets in the areas of healthcare, technology and internet, and cleantech has invested in more than 70 healthcare companies, that span most sectors of life sciences from pharmaceuticals and medical devices to healthcare IT, diagnostics and select healthcare services.

The firm’s US fund is focused on early-stage health care opportunities in the US with potential market opportunities in China, and the USA team is spread out across multiple locations across the country. The firm intends to lead, co-lead, or co-invest in US-based private companies in biotech for therapeutics, Medtech, and digital health technologies, with equity investments ranging from $5 to $20 million. The firm will not make public company investments.

The firm is open to many sectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is most interested in breakthrough products and technologies that address a large unmet need. The firm seeks investments in 510K devices and will invest in devices in the PMA pathway depending on stage, preferably clinical or later. In therapeutics, the firm is modality-agnostic but generally seeking opportunities that are past the pre-clinical stage. The firm is also interested in enabling technologies for drug discovery and development, and other healthcare-related technologies in the “digital-health” space.

The firm is seeking to invest in companies with novel ideas and technology and experienced and passionate management. Given the firm’s slogan of “inspiring people with the wisdom to succeed with diligence,” The firm’s team is “hands-on” and typically assumes a board seat after an investment. In general, the firm invests globally and prefers companies that have upside opportunities in China and can leverage the firm’s China network and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Evergreen Venture Fund Invests in Global Therapeutics Companies Across a Wide Stage of Development, Open to All Disease Areas

14 Apr

An evergreen venture fund based in the US is a flexible investor; the firm’s initial allocations vary depending on the company’s developmental stage, from $150,000 to several million dollars. The firm is open to being a lead investor, and will consider opportunities globally. The firm is open to investing in both privately held companies and publicly traded companies.

The firm invests in the therapeutics sector. The firm only invests in companies with assets that are at the clinical phase of development, and which are based on solidly vetted science. The firm is agnostic in therapeutic indications and will consider opportunities in any area of medicine.

The firm likes to invest as part of a syndicate in science at a US or OUS company that will create a value inflection from a well executed study. The firm has a flexible approach to management teams and may be a more hands-on investor if the management team has limited business experience. The firm requires a high level of transparency from portfolio companies, and guides portfolio companies in planning studies that will create real value inflection points for the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →